Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Consensus Rating of “Hold” by Brokerages

Halozyme Therapeutics, Inc. (NASDAQ:HALO) has earned an average rating of “Hold” from the twelve ratings firms that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and six have issued a buy rating on the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $78.5556.

Several equities research analysts have issued reports on the company. Weiss Ratings downgraded Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a report on Tuesday, February 24th. TD Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a research report on Wednesday, February 18th. HC Wainwright restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Thursday, January 29th. Wells Fargo & Company lifted their target price on shares of Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an “equal weight” rating in a report on Thursday, February 19th. Finally, The Goldman Sachs Group reissued a “sell” rating and issued a $56.00 price target on shares of Halozyme Therapeutics in a report on Thursday, December 4th.

Halozyme Therapeutics Price Performance

Shares of NASDAQ HALO opened at $63.66 on Friday. The company has a quick ratio of 3.66, a current ratio of 4.66 and a debt-to-equity ratio of 43.89. The business’s 50 day moving average price is $72.42 and its two-hundred day moving average price is $70.53. The company has a market cap of $7.51 billion, a PE ratio of 25.57, a price-to-earnings-growth ratio of 0.26 and a beta of 0.98. Halozyme Therapeutics has a twelve month low of $47.50 and a twelve month high of $82.22.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.92 by ($2.16). The business had revenue of $451.77 million during the quarter, compared to analyst estimates of $446.13 million. Halozyme Therapeutics had a net margin of 22.69% and a return on equity of 136.12%. The business’s quarterly revenue was up 51.6% on a year-over-year basis. During the same period in the previous year, the business earned $1.26 earnings per share. On average, analysts predict that Halozyme Therapeutics will post 4.73 EPS for the current year.

Insider Activity

In related news, Director Bernadette Connaughton sold 2,000 shares of the business’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $70.25, for a total value of $140,500.00. Following the completion of the sale, the director directly owned 40,123 shares in the company, valued at $2,818,640.75. The trade was a 4.75% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Cortney Caudill sold 20,000 shares of the company’s stock in a transaction on Monday, March 9th. The shares were sold at an average price of $67.80, for a total value of $1,356,000.00. Following the completion of the transaction, the chief operating officer directly owned 14,366 shares in the company, valued at approximately $974,014.80. This represents a 58.20% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 90,857 shares of company stock valued at $6,500,287. 2.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Halozyme Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. CWM LLC boosted its holdings in Halozyme Therapeutics by 2,136.0% in the 3rd quarter. CWM LLC now owns 23,881 shares of the biopharmaceutical company’s stock valued at $1,751,000 after purchasing an additional 22,813 shares during the period. Arbor Investment Advisors LLC acquired a new position in shares of Halozyme Therapeutics during the 3rd quarter worth approximately $1,316,000. Monument Capital Management bought a new position in shares of Halozyme Therapeutics during the third quarter worth approximately $2,015,000. Pacer Advisors Inc. raised its position in shares of Halozyme Therapeutics by 2,054.7% in the third quarter. Pacer Advisors Inc. now owns 478,874 shares of the biopharmaceutical company’s stock valued at $35,121,000 after buying an additional 456,649 shares in the last quarter. Finally, Cardinal Capital Management acquired a new stake in shares of Halozyme Therapeutics in the third quarter valued at approximately $1,303,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.